How should I interpret biosimilar market share data?

Biosimilar market share varies dramatically by channel. In physician-office infusion (Part B), biosimilar adalimumab adoption exceeds 50% due to ASP-based reimbursement incentives. In retail pharmacy (Part D), adoption is under 20% because PBM formulary management, not substitution, drives product selection. Always segment biosimilar share data by channel, payer type, and geography for meaningful analysis.